Protocol for the Controlled evaLuation of Angiotensin Receptor blockers for COVID-19 respIraTorY disease (CLARITY): a randomised controlled trial
Field | Value | Language |
dc.contributor.author | Hockham, Carinna | en_AU |
dc.contributor.author | Kotwal, Sradha | en_AU |
dc.contributor.author | Wilcox, Arlen | en_AU |
dc.contributor.author | Bassi, Abhinav | en_AU |
dc.contributor.author | McGree, James | en_AU |
dc.contributor.author | Pollock, Carol | en_AU |
dc.contributor.author | Burrell, Louise M. | en_AU |
dc.contributor.author | Bathla, Nikita | en_AU |
dc.contributor.author | Kunigari, Mallikarjuna | en_AU |
dc.contributor.author | Rathore, Vinay | en_AU |
dc.contributor.author | John, Michael | en_AU |
dc.contributor.author | Lin, Enmoore | en_AU |
dc.contributor.author | Jenkins, Christine | en_AU |
dc.contributor.author | Ritchie, Angus | en_AU |
dc.contributor.author | McLachlan, Andrew | en_AU |
dc.contributor.author | Snelling, Thomas | en_AU |
dc.contributor.author | Jones, Mark | en_AU |
dc.contributor.author | Jha, Vivekanand | en_AU |
dc.contributor.author | Jardine, Meg | en_AU |
dc.contributor.author | en_AU | |
dc.date.accessioned | 2021-09-16T22:00:31Z | |
dc.date.available | 2021-09-16T22:00:31Z | |
dc.date.issued | 2021 | |
dc.identifier.uri | https://hdl.handle.net/2123/26067 | |
dc.description.abstract | BackgroundSARS-CoV-2 binds to membrane-bound angiotensin-converting enzyme 2 (ACE2) which may result in downregulation of membrane-bound ACE2. ACE2 is a key regulator of the renin-angiotensin system (RAS) and is responsible for degrading angiotensin II and thereby counteracting its pro-inflammatory, pro-fibrotic effects mediated through the angiotensin II type 1 receptor (AT1R). As AT1R is directly blocked by angiotensin receptor blockers (ARBs), these agents may offer a safe, low-cost solution for reducing COVID-19 respiratory outcomes.Methods and discussionCLARITY is a pragmatic, adaptive, two-arm, multi-centre, comparative effectiveness phase III randomised controlled trial that examines whether ARBs reduce COVID-19 severity among high-risk patients. Recruiting in India and Australia, the trial will compare treatment with a maximum tolerated daily dose of an ARB to standard of care. Treatment allocation is blinded in India but open-label in Australia due to interruptions to placebo supply in the latter. The primary endpoint is a 7-point ordinal scale of clinical states, ranging from no limitation of activities (category 1) to death (category 7), assessed on day 14. Secondary outcomes include the 7-point scale assessed at day 28 and 28- and 90-day mortality. The design adapts the sample size based on accumulating data via frequent interim analyses and the use of predictive probability to determine whether the current sample size is sufficient or continuing accrual would be futile. The trial commenced recruitment on 18 August 2020.Trial registrationClinicalTrials.gov, NCT04394117. Registered on 19 May 2020. Clinical Trial Registry of India: CTRI/2020/07/026831) | en_AU |
dc.language.iso | en | en_AU |
dc.subject | COVID-19 | en_AU |
dc.subject | Coronavirus | en_AU |
dc.title | Protocol for the Controlled evaLuation of Angiotensin Receptor blockers for COVID-19 respIraTorY disease (CLARITY): a randomised controlled trial | en_AU |
dc.type | Article | en_AU |
dc.subject.asrc | 1102 Cardiorespiratory Medicine and Haematology | en_AU |
dc.subject.asrc | 11 Medical and Health Sciences | en_AU |
dc.identifier.doi | 10.1186/s13063-021-05521-0 | |
dc.relation.other | National Health and Medical Research Council | en_AU |
Associated file/s
There are no files associated with this item.
Associated collections